Showing Results for: “type diabetes”

Today, the American Diabetes Association (ADA) sent a letter to the Centers for Disease Control and Prevention (CDC) urging them to take immediate steps to update their guidance on the risk people with type 1 diabetes (T1D) face with COVID-19 and acknowledge that people with both T1D and type 2 diabetes (T2D) should be prioritized equally in the rollout of the vaccine. This change is particularly important because more recent clinical evidence demonstrates that COVID-19 severity is more than tripled in individuals with T1D and time-sensitive, as states are now operationalizing vaccine rollouts

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the

Analysis of large international DAPA-HF trial participants notes diabetes prevention benefit in patients with heart failure who took 10 mg of medication The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D), according to the study, “Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF,” presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. The original DAPA-HF trial was a phase 3 placebo-controlled international study of

Reduced hospitalization rates among people with low self-monitoring of blood glucose (SMBG) are especially pronounced People using Abbott’s FreeStyle Libre, a sensor-based glucose monitoring system, experienced a considerable decrease in ketoacidosis-related hospitalizations—52% for type 1 diabetes and 47% for type 2 diabetes—according to the study titled “Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study,” presented today at the American

Data Shows Potential Breakthrough Treatment Option for Glucose Management in Adolescents with Uncontrolled Diabetes Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo. The trial was presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine . The findings come at a time when cases of type 2 diabetes among youth have more than doubled, since the pandemic

American Heart Association ® and American Diabetes Association ® reveal results of Know Diabetes by Heart ™ survey and share practical tips for staying on track with health goals through the holiday season Nearly half (49%) of people living with type 2 diabetes said managing their condition during a typical fall and winter holiday season is more difficult than other times of the year, according to a new survey for the American Heart Association and American Diabetes Association. The online survey of more than 1,000 U.S. adults 45 and older completed by real-time market research platform

Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care The iLet bionic pancreas (BP)¹ significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy of either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), according to the study, “First Human Study Testing the iLet, a Purpose-Built Bionic Pancreas Platform,” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone